1. Home
  2. DFIN vs CGON Comparison

DFIN vs CGON Comparison

Compare DFIN & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DFIN
  • CGON
  • Stock Information
  • Founded
  • DFIN 1983
  • CGON 2010
  • Country
  • DFIN United States
  • CGON United States
  • Employees
  • DFIN N/A
  • CGON N/A
  • Industry
  • DFIN Other Consumer Services
  • CGON
  • Sector
  • DFIN Consumer Discretionary
  • CGON
  • Exchange
  • DFIN Nasdaq
  • CGON NYSE
  • Market Cap
  • DFIN 1.4B
  • CGON 1.3B
  • IPO Year
  • DFIN N/A
  • CGON 2024
  • Fundamental
  • Price
  • DFIN $44.96
  • CGON $22.37
  • Analyst Decision
  • DFIN Strong Buy
  • CGON Strong Buy
  • Analyst Count
  • DFIN 3
  • CGON 10
  • Target Price
  • DFIN $68.67
  • CGON $65.11
  • AVG Volume (30 Days)
  • DFIN 395.8K
  • CGON 1.4M
  • Earning Date
  • DFIN 04-30-2025
  • CGON 05-08-2025
  • Dividend Yield
  • DFIN N/A
  • CGON N/A
  • EPS Growth
  • DFIN 13.76
  • CGON N/A
  • EPS
  • DFIN 3.06
  • CGON N/A
  • Revenue
  • DFIN $781,900,000.00
  • CGON $1,139,000.00
  • Revenue This Year
  • DFIN $3.52
  • CGON N/A
  • Revenue Next Year
  • DFIN $4.79
  • CGON $16,237.24
  • P/E Ratio
  • DFIN $14.65
  • CGON N/A
  • Revenue Growth
  • DFIN N/A
  • CGON 461.08
  • 52 Week Low
  • DFIN $37.80
  • CGON $14.80
  • 52 Week High
  • DFIN $71.01
  • CGON $46.99
  • Technical
  • Relative Strength Index (RSI)
  • DFIN 55.47
  • CGON 52.55
  • Support Level
  • DFIN $39.88
  • CGON $19.91
  • Resistance Level
  • DFIN $42.30
  • CGON $21.60
  • Average True Range (ATR)
  • DFIN 2.08
  • CGON 1.75
  • MACD
  • DFIN 0.83
  • CGON 0.57
  • Stochastic Oscillator
  • DFIN 88.20
  • CGON 98.95

About DFIN Donnelley Financial Solutions Inc.

Donnelley Financial Solutions Inc is a risk and compliance solutions company. The company provides regulatory filing and deal solutions via its software-as-a-service, technology-enabled services, and print and distribution solutions to public and private companies, mutual funds, and other regulated investment firms. The company operates in four segments: Capital Markets - Software Solutions, Capital Markets - Compliance and Communications Management, Investment Companies - Software Solutions and Investment Companies - Compliance and Communications Management. Its geographical segments are the United States( USA), Europe, Asia, Canada, and others, of which the USA accounts for the vast majority of its total revenue.

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

Share on Social Networks: